Journal
CELL
Volume 147, Issue 5, Pages 1011-1023Publisher
CELL PRESS
DOI: 10.1016/j.cell.2011.09.055
Keywords
-
Categories
Funding
- NIH [HL59949, 5R01MH084894, MH084894, MH091360, DA026434, F30HL097582, SRC1DA02811202, 1R01DA02694702]
- NARSAD
- Dainippon Sumitomo Pharma
- Maltz Family Foundation
- National Science Foundation [TG-MCB080109N]
- Ministerio de Ciencia e Innovacion, Spain
Ask authors/readers for more resources
Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT2A G protein-coupled receptor (GPCR), the 2AR, which signals via a G(q) heterotrimeric G protein. The closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 2AR function, but they lack comparable neuropsychological effects. Why some but not all 2AR inhibitors exhibit antipsychotic properties remains unresolved. We now show that a heteromeric complex between the 2AR and the Gi-linked GPCR, metabotropic glutamate 2 receptor (mGluR2), integrates ligand input, modulating signaling output and behavioral changes. Serotonergic and glutamatergic drugs bind the mGluR2/2AR heterocomplex, which then balances Gi- and Gq-dependent signaling. We find that the mGluR2/2AR-mediated changes in Gi and Gq activity predict the psychoactive behavioral effects of a variety of pharmocological compounds. These observations provide mechanistic insight into antipsychotic action that may advance therapeutic strategies for disorders including schizophrenia and dementia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available